AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc.verified

ACRX

Price:

$0.86

Market Cap:

$14.58M

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2011-02-11

Stock Exchange

NASDAQ

Ticker

ACRX

The Enterprise Value as of September 2024 (TTM) for AcelRx Pharmaceuticals, Inc. (ACRX) is 1.19M

According to AcelRx Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.19M. This represents a change of -53.06% compared to the average of 2.54M of the last 4 quarters.

AcelRx Pharmaceuticals, Inc. (ACRX) Historical Enterprise Value (quarterly & annually)

How has ACRX Enterprise Value performed in the past?

The mean historical Enterprise Value of AcelRx Pharmaceuticals, Inc. over the last ten years is 1.14B. The current 1.19M Enterprise Value has changed -89.53% with respect to the historical average. Over the past ten years (40 quarters), ACRX's Enterprise Value was at its highest in in the March 2014 quarter at 455.62M. The Enterprise Value was at its lowest in in the September 2023 quarter at -3669360.00.

Quarterly (TTM)
Annual

Average

1.14B

Median

78.32M

Minimum

11.89M

Maximum

10.48B

AcelRx Pharmaceuticals, Inc. (ACRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of AcelRx Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 88.04%

Maximum Annual Enterprise Value = 10.48B

Minimum Annual Increase = -83.73%

Minimum Annual Enterprise Value = 11.89M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202310.48B88.04%
202211.89M-83.73%
202173.08M-29.76%
2020104.04M-42.88%
2019182.15M209.05%
201858.94M-3.96%
201761.37M3.92%
201659.05M-29.32%
201583.56M-67.50%
2014257.13M-31.52%

AcelRx Pharmaceuticals, Inc. (ACRX) Average Enterprise Value

How has ACRX Enterprise Value performed in the past?

The current Enterprise Value of AcelRx Pharmaceuticals, Inc. (ACRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

3.52B

5-year avg

2.17B

10-year avg

1.14B

AcelRx Pharmaceuticals, Inc. (ACRX) Enterprise Value vs. Peers

How is ACRX’s Enterprise Value compared to its peers?

AcelRx Pharmaceuticals, Inc.’s Enterprise Value is less than Mallinckrodt plc (2.62B), less than Lifecore Biomedical, Inc. (279.79M), less than Lucy Scientific Discovery Inc. (2.06M), less than Alimera Sciences, Inc. (362.58M), greater than Adamis Pharmaceuticals Corporation (-6593458674.00), less than Shuttle Pharmaceuticals Holdings, Inc. (4.22M), less than Catalent, Inc. (15.61B), less than Tilray Brands, Inc. (1.68B), less than Aquestive Therapeutics, Inc. (480.04M), greater than Evoke Pharma, Inc. (-712315.00), greater than Guardion Health Sciences, Inc. (-2032592.00), less than Organogenesis Holdings Inc. (397.69M), less than Agile Therapeutics, Inc. (7.87M), less than Assertio Holdings, Inc. (111.75M), less than Amneal Pharmaceuticals, Inc. (5.40B),

Build a custom stock screener for AcelRx Pharmaceuticals, Inc. (ACRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AcelRx Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

AcelRx Pharmaceuticals, Inc. (ACRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like AcelRx Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is AcelRx Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for AcelRx Pharmaceuticals, Inc. (ACRX)?

What is the 3-year average Enterprise Value for AcelRx Pharmaceuticals, Inc. (ACRX)?

What is the 5-year average Enterprise Value for AcelRx Pharmaceuticals, Inc. (ACRX)?

How does the current Enterprise Value for AcelRx Pharmaceuticals, Inc. (ACRX) compare to its historical average?